These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33335255)

  • 1. Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum.
    Tapia-Alveal C; Olsen TR; Worgall TS
    Commun Biol; 2020 Dec; 3(1):781. PubMed ID: 33335255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microfluidic isolation of aptamers with affinity towards multiple myeloma monoclonal immunoglobulins.
    Olsen TR; Tapia-Alveal C; Wen K; Worgall TS; Stojanovic MN; Lin Q
    Biomed Microdevices; 2022 Dec; 25(1):3. PubMed ID: 36480127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
    Bal S; Costa LJ
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
    Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
    J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
    Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
    Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
    Guan L; Su W; Zhong J; Qiu L
    Clin Chim Acta; 2024 Jan; 552():117623. PubMed ID: 37924928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of minimal residual disease detection in multiple myeloma].
    Takamatsu H
    Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.
    Rasmussen T; Poulsen TS; Honoré L; Johnsen HE
    Exp Hematol; 2000 Sep; 28(9):1039-45. PubMed ID: 11008016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular detection of minimal residual disease in multiple myeloma.
    Bai Y; Orfao A; Chim CS
    Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
    Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
    Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What to do with minimal residual disease testing in myeloma.
    Manasanch EE
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease analysis in myeloma - when, why and where.
    Yanamandra U; Kumar SK
    Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
    Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
    Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
    Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
    Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.
    Thoren KL
    Semin Hematol; 2018 Jan; 55(1):41-43. PubMed ID: 29759153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
    Rustad EH; Boyle EM
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.
    Avet-Loiseau H
    Am Soc Clin Oncol Educ Book; 2016; 35():e425-30. PubMed ID: 27249750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.